Synkrino Biotherapeutics
Synkrino's AI, SATIS is a powerful, unbiased discovery system for…
Y CombinatorSummer 2018ActiveHealthcareDrug Discovery and DeliveryAI-powered Drug DiscoveryBiotech
What they do
Problem
Biotherapeutic discovery is slow and biased, making it difficult to identify promising drug candidates efficiently.
Solution
SATIS is an AI-driven, unbiased discovery system that helps identify and prioritize biotherapeutic candidates.
Who it's for
Biopharma and biotechnology R&D teams developing biotherapeutics.
Founders
Jason Barbour
Founder/CEO
David Ott
Founder/CTO
Company timeline
- YC batchSummer 2018
- StatusActive
- Team size2 people
- LocationOakland, CA, USA
Similar startups
1910
Multimodal AI Platform for Modality Agnostic Drug Discovery™
Nabla Bio
We use AI to design antibodies for intractable diseases
CellChorus
The dynamic single-cell analysis company
Output Biosciences
Teaching Generative AI the Language of Biology
CellType
The agentic drug company. We simulate human biology.
Insitro
Drug design is fundamentally a data science problem. Naturally, data…